{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-myeloma/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field fb2de5e3-78eb-4fc9-8739-a0a38df7e27b --><h2>Prognosis</h2><!-- end field fb2de5e3-78eb-4fc9-8739-a0a38df7e27b -->","summary":"","htmlStringContent":"<!-- begin item 861f5d76-2259-427f-9191-794129a2adf7 --><!-- begin field 48666af6-e843-4240-9a69-207223d4039c --><ul><li><strong>Multiple myeloma is usually an incurable disease. </strong><ul><li>Disease course is variable with survival times ranging from a few weeks to more than 20 years.</li></ul></li><li><strong>Advances in treatment and supportive care have markedly improved survival in the past 40 years.</strong><ul><li>Most people respond to initial treatment and enter a period of disease stability. Subsequent relapses become less responsive to treatment, leading to end-stage disease.</li><li>Some treated patients survive progression free for more than 10 years but around 10% die within 1 year of diagnosis (often as a result of infection, renal failure, or cardiovascular event).</li><li>In England, of people diagnosed with myeloma between 2013 and 2017 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">CRUK, 2020</a>]:<ul><li>82.7% survived for 1 year or more.</li><li>52.3% survived their disease for 5 years or more.</li><li>29.1% are predicted to survive their disease for 10 years or more.</li></ul></li></ul></li><li><strong>Survival is related to many factors including age and stage at diagnosis.</strong> In England [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">CRUK, 2020</a>]:<ul><li>Around three quarters of people diagnosed with myeloma aged 15–49 years survive their disease for 5 years or more, compared with one quarter of people diagnosed aged 80 years and over (2009–2013).</li><li>Around 96% of people diagnosed at Stage 1 survive their disease for at least 1 year, compared with 80% of patients diagnosed at Stage 3.</li></ul></li><li><strong>Unfavourable prognostic signs at presentation include</strong> beta-2 microglobinaemia, renal impairment, high plasma cell counts, diffuse multiple bone lesions or fracture, marked anaemia, and hypercalcaemia.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Smith, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Caers, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Kumar, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">MFA, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Mohty, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Atkin, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">CRUK, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Guzdar, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Herget, 2020</a>]</p><!-- end field 48666af6-e843-4240-9a69-207223d4039c --><!-- end item 861f5d76-2259-427f-9191-794129a2adf7 -->","topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","lastRevised":"Last revised in January 2021","chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","fullItemName":"Management","slug":"management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c45f4611-e831-51b1-ae27-0421b247f510","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}